127 related articles for article (PubMed ID: 1967551)
1. Binding of an optically pure photoaffinity analogue of verapamil, LU-49888, to P-glycoprotein from multidrug-resistant human leukemic cell lines.
Qian XD; Beck WT
Cancer Res; 1990 Feb; 50(4):1132-7. PubMed ID: 1967551
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
Beck WT; Cirtain MC; Danks MK; Felsted RL; Safa AR; Wolverton JS; Suttle DP; Trent JM
Cancer Res; 1987 Oct; 47(20):5455-60. PubMed ID: 2888532
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein-independent mechanism of resistance to VP-16 in multidrug-resistant tumor cell lines: pharmacokinetic and photoaffinity labeling studies.
Politi PM; Arnold ST; Felsted RL; Sinha BK
Mol Pharmacol; 1990 Jun; 37(6):790-6. PubMed ID: 1972771
[TBL] [Abstract][Full Text] [Related]
4. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells.
Yusa K; Tsuruo T
Cancer Res; 1989 Sep; 49(18):5002-6. PubMed ID: 2569930
[TBL] [Abstract][Full Text] [Related]
5. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.
Hendricks CB; Rowinsky EK; Grochow LB; Donehower RC; Kaufmann SH
Cancer Res; 1992 Apr; 52(8):2268-78. PubMed ID: 1348448
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
[TBL] [Abstract][Full Text] [Related]
7. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines.
Ford JM; Bruggemann EP; Pastan I; Gottesman MM; Hait WN
Cancer Res; 1990 Mar; 50(6):1748-56. PubMed ID: 1968358
[TBL] [Abstract][Full Text] [Related]
8. Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng.
Choi CH; Kang G; Min YD
Planta Med; 2003 Mar; 69(3):235-40. PubMed ID: 12677527
[TBL] [Abstract][Full Text] [Related]
9. Synthetic isoprenoid photoaffinity labeling of P-glycoprotein specific to multidrug-resistant cells.
Akiyama S; Yoshimura A; Kikuchi H; Sumizawa T; Kuwano M; Tahara Y
Mol Pharmacol; 1989 Nov; 36(5):730-5. PubMed ID: 2573823
[TBL] [Abstract][Full Text] [Related]
10. Characterization of rhodamine 123 binding to P-glycoprotein in human multidrug-resistant cells.
Nare B; Prichard RK; Georges E
Mol Pharmacol; 1994 Jun; 45(6):1145-52. PubMed ID: 7912815
[TBL] [Abstract][Full Text] [Related]
11. Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog.
Akiyama S; Cornwell MM; Kuwano M; Pastan I; Gottesman MM
Mol Pharmacol; 1988 Feb; 33(2):144-7. PubMed ID: 2893251
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of JNK/SAPK activity is associated with the cross-resistance to P-glycoprotein-unrelated drugs in multidrug-resistant FM3A/M cells overexpressing P-glycoprotein.
Kang CD; Ahn BK; Jeong CS; Kim KW; Lee HJ; Yoo SD; Chung BS; Kim SH
Exp Cell Res; 2000 Apr; 256(1):300-7. PubMed ID: 10739677
[TBL] [Abstract][Full Text] [Related]
13. Direct interaction between verapamil and doxorubicin causes the lack of reversal effect of verapamil on P-glycoprotein mediated resistance to doxorubicin in vitro using L1210/VCR cells.
Breier A; Drobná Z; BarancĂk M
Neoplasma; 1998; 45(4):248-53. PubMed ID: 9890669
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of flow cytometry for multidrug resistance detection in low resistance K562 cells using daunorubicin and monoclonal antibodies.
Van Acker KL; Van Hove LM; Boogaerts MA
Cytometry; 1993 Oct; 14(7):736-46. PubMed ID: 7902231
[TBL] [Abstract][Full Text] [Related]
15. A unique human ovarian carcinoma cell line expressing CD34 in association with selection for multidrug resistance.
Minderman H; Vanhoefer U; Toth K; Minderman MD; Rustum YM
Cancer; 1996 Dec; 78(11):2427-36. PubMed ID: 8941015
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen aziridine, a novel affinity probe for P-glycoprotein in multidrug resistant cells.
Safa AR; Roberts S; Agresti M; Fine RL
Biochem Biophys Res Commun; 1994 Jul; 202(1):606-12. PubMed ID: 7913604
[TBL] [Abstract][Full Text] [Related]
17. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.
Piwnica-Worms D; Chiu ML; Budding M; Kronauge JF; Kramer RA; Croop JM
Cancer Res; 1993 Mar; 53(5):977-84. PubMed ID: 8094997
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines.
Slovak ML; Hoeltge GA; Dalton WS; Trent JM
Cancer Res; 1988 May; 48(10):2793-7. PubMed ID: 2896069
[TBL] [Abstract][Full Text] [Related]
19. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells.
Wan CK; Zhu GY; Shen XL; Chattopadhyay A; Dey S; Fong WF
Biochem Pharmacol; 2006 Sep; 72(7):824-37. PubMed ID: 16889754
[TBL] [Abstract][Full Text] [Related]
20. Characterization of monoclonal antibodies recognizing a Mr 180,000 P-glycoprotein: differential expression of the Mr 180,000 and Mr 170,000 P-glycoproteins in multidrug-resistant human tumor cells.
Meyers MB; Rittmann-Grauer L; O'Brien JP; Safa AR
Cancer Res; 1989 Jun; 49(12):3209-14. PubMed ID: 2566379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]